Aktien Sensor

GSK PLC’s plans for its multiple myeloma treatment Blenrep have been put on hold after the FDA delayed its decision on the drug’s approval.

Argenx SE will release its half-year 2025 financial results and second-quarter business update on July 31, 2025.

Astellas Pharma’s stock price has surged significantly due to the company’s growing appeal to investors and its strong focus on oncology and targeted therapies.

Roche Holding AG has delivered a strong performance in the first half of the year, driven by steady growth in its pharmaceutical business and innovative partnerships, solidifying its position as a leader in the industry.

Bristol-Myers Squibb Co is navigating market volatility while making significant strides in developing groundbreaking treatments for precision oncology, including a recent European Commission approval for a new multiple myeloma treatment.

Sanofi’s aggressive expansion strategy is a high-stakes gamble that could either propel the company to new heights or lead to a catastrophic collapse.

Sartorius Stedim Biotech has reported significant growth in its quarterly earnings, driven by strong performance across various industries and a positive outlook for 2025.

Eurofins Scientific SE has delivered a solid first half performance, meeting expectations with a 5.7% revenue increase and reaffirming its ambitious objectives for 2025 and 2027.

Vertex Pharmaceuticals has received approval for ALYFTREK, a new cystic fibrosis treatment, in Canada, expanding options for up to 60 patients.

Alnylam Pharmaceuticals has gained a positive rating from Truist Securities, citing the company’s promising pipeline and growth prospects in the treatment of human diseases.